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Abstract
Objectives To compare the cost-effectiveness of first-line gefitinib, erlotinib, afatinib, and osimertinib in patients with non-
small cell lung cancer (NSCLC) harbouring epidermal growth factor receptor (EGFR) mutations.
Methods A systematic review and network meta-analysis (NMA) were conducted to compare the relative efficacy of gefi-
tinib, erlotinib, afatinib, and osimertinib in EGFR-mutated NSCLC. To assess the cost-effectiveness of these treatments, a 
Markov model was developed from Dutch societal perspective. The model was based on the clinical studies included in the 
NMA. Incremental costs per life-year (LY) and per quality-adjusted life-year (QALY) gained were estimated. Deterministic 
and probabilistic sensitivity analyses (PSA) were conducted.
Results Total discounted per patient costs for gefitinib, erlotinib, afatinib, and osimertinib were €65,889, €64,035, €69,418, 
and €131,997, and mean QALYs were 1.36, 1.39, 1.52, and 2.01 per patient, respectively. Erlotinib dominated gefitinib. 
Afatinib versus erlotinib yielded incremental costs of €27,058/LY and €41,504/QALY gained. Osimertinib resulted in 
€91,726/LY and €128,343/QALY gained compared to afatinib. PSA showed that gefitinib, erlotinib, afatinib, and osimer-
tinib had 13%, 19%, 43%, and 26% probability to be cost-effective at a threshold of €80,000/QALY. A price reduction of 
osimertinib of 30% is required for osimertinib to be cost-effective at a threshold of €80,000/QALY.
Conclusions Osimertinib has a better effectiveness compared to all other TKIs. However, at a Dutch threshold of €80,000/
QALY, osimertinib appears not to be cost-effective.
Keywords Cost-effectiveness analysis · Non-small cell lung cancer · EGFR-TKI · Gefitinib · Erlotinib · Afatinib · 
Osimertinib
JEL Classification I19 · C59 · C69
Introduction
Lung cancer is the leading cause of cancer-related mortal-
ity in The Netherlands and worldwide, with 10,346 lung 
cancer deaths in The Netherlands in 2014 [1]. Non-small 
cell lung cancer (NSCLC) is the most common type of lung 
cancer with 80–85% of all cases [2]. At diagnosis, many 
patients with NSCLC are already in an advanced disease 
stage (IIIB or IV) and thus ineligible for surgical resection 
[3]. Platinum-based therapy is the standard first-line treat-
ment for advanced NSCLC, which provides a median overall 
survival (OS) of about 8 months [4]. Nowadays, molecularly 
targeted agents are of high importance as treatment strate-
gies for lung cancer patients [5]. For several cancer types, 
these targeted agents have come with improved outcomes, 
but also increased costs [6].
In NSCLC, mutations of the epidermal growth factor recep-
tor (EGFR) play an important role in the growth and progres-
sion of tumour cells [7]. Prevalence of EGFR mutations is the 
highest in Asia with over 50% of all Asian patients with lung 
cancer type adenocarcinoma [8]. Among Dutch patients with 
NSCLC, the frequency of EGFR mutations is about 11% [9, 
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10]. Currently, three first-line EGFR tyrosine kinase inhibi-
tors (TKIs) are used in clinical practice: gefitinib, erlotinib, 
and afatinib. These drugs have shown significantly improved 
progression-free survival (PFS) as the first-line treatment, 
compared to platinum-based therapy, in patients with EGFR 
mutation-positive (exon 19 deletion or exon 21 L858R mutation) 
NSCLC [11–18]. Osimertinib, a third-generation EGFR-TKI, is 
used as the second-line treatment in clinical practice. Recently, 
a randomised-controlled trial (RCT) showed a better efficacy 
of osimertinib compared to gefitinib and erlotinib as the first-
line treatment. Moreover, clinical studies showed the ability of 
osimertinib to penetrate the central nervous system (CNS). This 
may be an advantage over the standard treatment, as it could 
decrease the occurrence of CNS progression [19]. Therefore, 
osimertinib is expected to be used as the first-line treatment in 
clinical practice in the near future. Clear direct evidence of the 
differences between gefitinib, erlotinib, afatinib, and osimerti-
nib in terms of efficacy and toxicity is lacking as head-to-head 
comparisons are not available for all these TKIs. Thus, it is still 
uncertain whether one TKI is more favourable over the others 
in terms of efficacy and toxicity. Network meta-analysis (NMA) 
enables comparison of direct and indirect evidence across trials 
to synthesise the efficacy of different TKIs. Several NMAs on 
TKIs did not show significant differences between these drugs 
[20–24]. However, the outcomes of the NMAs differed from 
each other, which may be due to differences in the selection of 
studies and data [25]. Therefore, we built a new NMA of the 
efficacy of first-line gefitinib, erlotinib, afatinib, and osimertinib. 
In addition, lung cancer has a substantial economic burden on 
the health care system, with total mean hospital costs of €33,143 
per patient with NSCLC in The Netherlands [26]. For NSCLC, 
furthermore, TKIs are administered until disease progression 
or unacceptable toxicity, which increases the drug acquisition 
costs. Nowadays, the comparative costs and effects are of grow-
ing importance for decision-makers [27]. Therefore, information 
on the incremental value of new treatments in terms of effects 
and costs is needed for medical resource optimisation. However, 
not only the acquisition costs of the drugs should be taken into 
account in the assessment of the cost-effectiveness, but also, 
for example, costs of adverse event management, travelling, 
and productivity losses [28]. Hence, we aimed to assess the 
cost-effectiveness of first-line gefitinib, erlotinib, afatinib, and 
osimertinib in patients with stage IIIB/IV NSCLC harbouring 
EGFR mutations (exon 19 deletion or exon 21 L858R mutation) 
in The Netherlands from a Dutch societal perspective.
Methods
Systematic review and network meta‑analysis
A systematic search of several databases (PubMed, 
EMBASE, and Cochrane Library) was conducted to 
identify phase IIB/III RCTs of first-line EGFR-TKI 
(including gefitinib, erlotinib, afatinib, or osimertinib) 
compared to another TKI or platinum-based therapy. 
Search strategy and inclusion and exclusion criteria can 
be found in Appendix I. Reference lists of published stud-
ies were also checked as additional information. The lit-
erature review was conducted by two reviewers (MH and 
CU). After screening titles and abstracts and then full-
text reading of the records found by the systematic review, 
12 unique RCTs were included in the NMA [11–17, 19, 
29–32]. Quality and risk of bias of the included RCTs 
were assessed using the Cochrane Collaboration’s tool for 
assessing risk of bias. According to this assessment, all 
RCTs were classified as having acceptable quality and low 
risk of bias [25]. Data on patient characteristics, interven-
tions, comparators, and treatment effects [PFS, OS, and 
adverse events (AEs)] were extracted. For the NMA, the 
outcomes of interest were PFS and OS. Since no separate 
HRs of osimertinib versus gefitinib or osimertinib versus 
erlotinib were reported in the FLAURA trial, the HRs of 
PFS and OS were assumed to be the same for both com-
parisons. A fixed-effects network meta-analysis in Win-
BUGS 1.4 was built within a Bayesian framework by use 
of an adapted version of WinBUGS code from Dias et al. 
[33]. Due to the limited number of RCTs per TKI arm, 
heterogeneity could not be appropriately assessed. There-
fore, a fixed-effect NMA was considered as appropriate. 
The methods of the NMA are described in more detail 
in Appendix I and in a previous study [34]. The results 
of the NMA are presented in Table 1. Osimertinib had 
a significantly better PFS and OS compared to gefitinib, 
erlotinib, and afatinib.
Model construction
A Markov model was constructed simulating the transi-
tion between three health states: progression-free, progres-
sion, and death, in which death was an absorbing state. A 
cycle length of 30 days was used for the model, which is 
an appropriate length given the rate at which lung cancer 
develops. In this model, during each cycle, patients with 
EGFR-mutated NSCLC move between the health states 
according to the transition probabilities. In each cycle, 
patients could remain progression-free, may progress, or 
die. A lifetime time horizon was used, in line with the 
Dutch guidelines [28], accounting for all relevant costs 
and effects of TKI therapies for patients with EGFR muta-
tions. Half-cycle correction was applied to both costs and 
effects. Effects are expressed in life-years (LYs) gained 
and in quality-adjusted life-years (QALYs) gained. Out-
comes are presented as incremental cost-effectiveness 
ratios (ICERs), i.e., incremental costs per LY gained and 
incremental costs per QALY gained.
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Clinical effectiveness
Estimates of the clinical effectiveness in terms of pooled 
HRs were derived from the NMA. Since HRs only convey 
information on comparative effectiveness, whereas a model 
requires absolute estimates of PFS and OS, we used an indi-
rect approach to estimate the transitions of patients treated 
with TKIs in the model. The NMA did not only include the 
four TKIs, but also chemotherapy. Thus, we first explored 
the Kaplan–Meier (KM) curves of PFS and OS for patients 
with EGFR mutations treated with chemotherapy from the 
EURTAC trial of erlotinib versus chemotherapy. According 
to clinical experts, the data of the chemotherapy patients in 
the EURTAC trial [15] were deemed as most representative 
for our study as patient characteristics of that trial are most 
similar to the Dutch patient population eligible for TKIs 
(i.e., Caucasian population, mainly adenocarcinoma histol-
ogy, mainly stage IV NSCLC). However, as the time horizon 
of the model is life time, whereas the KM curves are trun-
cated at 40 months, where 15% of the patients are still alive, 
it was necessary to extrapolate the KM curve using a para-
metric survival curve. Since we had no access to the individ-
ual patient data (IPD) of the EURTAC trial, the method of 
Hoyle and Henley [35] was used to recreate the IPD. Times 
and survival probabilities were read off from the published 
KM graph. Based on these survival probabilities and cor-
responding time and provided numbers at risk, the method 
of Hoyle and Henley estimated the underlying number of 
events and censorships in each time interval. By use of the 
statistical programme R, several survival distributions were 
fit to the recreated IPD. Based on the fit to the KM curve 
and the Akaike and Bayesian Information Criterion (AIC 
and BIC) estimates, a Weibull distribution was assessed as 
having the best goodness-of-fit for both PFS and OS (see 
Appendix II). The general Weibull equation is as follows 
(in which ‘t’ is time in months): S(t) = e−휆t훾 . Lambda and 
gamma parameters of the patients treated with chemotherapy 
in the EURTAC trial were used to estimate the parameters 
for gefitinib, erlotinib, afatinib, and osimertinib, as previ-
ously described in published studies [36, 37]. For example, 
the lambda parameter (scale parameter) for gefitinib was 
estimated by multiplying the lambda for chemotherapy by 
the pooled HR of gefitinib versus chemotherapy. The gamma 
parameter (shape parameter) was set equal to the gamma for 
chemotherapy. The same was done for erlotinib, afatinib, 
and osimertinib. These parameters were used as input to 
calculate the transitions of all TKIs.
For each TKI, the percentage of patients in progression-
free state at each time is determined by the values of the PFS 
curve at that time. Similarly, the percentage of patients in 
the death state is determined as 1 minus the OS curve at that 
time. From this, the percentage of patients in the progressed 
state follows, as the three states together should always add 
up to 100%.
After progression on first-line gefitinib, erlotinib, or 
afatinib, patients were tested for T790 M mutations. Patients 
who were T790 M mutation-positive received the second-
line osimertinib (50% of all patients) and patients who 
were T790 M mutation-negative were treated with pem-
etrexed–cisplatin [5, 38]. Patients who had progressive dis-
ease on the first-line osimertinib received the second-line 
pemetrexed–cisplatin treatment. Thus, the progressed health 
state is split into a ‘progression-free second line’ and ‘pro-
gressed second line’ health state for those patients receiving 
a second-line treatment. Clinical data of second-line osi-
mertinib and pemetrexed–cisplatin were derived from the 
literature [39, 40]. The KM curves of second-line osimer-
tinib and pemetrexed–cisplatin were also extrapolated by 
fitting various parametric functions. For both second-line 
PFS and OS, the exponential function was assessed as hav-
ing the best fit to the KM curves of second-line osimertinib 
and pemetrexed–cisplatin. The survival curves of all treat-
ment options and the estimation of the transition param-
eters can be found in Appendix II. After progression on 
Table 1  NMA results of PFS 
and OS
PFS progression-free survival, OS overall survival
PFS
 Chemotherapy 2.34 (2.04, 2.71) 2.76 (2.3, 3.34) 2.70 (2.27, 3.24) 5.63 (4.58, 7.01)
 0.43 (0.37, 0.49) Gefitinib 1.17 (0.98, 1.41) 1.15 (0.96, 1.39) 2.40 (2, 2.90)
 0.36 (0.3, 0.44) 0.85 (0.71, 1.02) Erlotinib 0.97 (0.77, 1.24) 2.04 (1.7, 2.46)
 0.37 (0.31, 0.44) 0.87 (0.72, 1.04) 1.03 (0.8, 1.3) Afatinib 2.07 (1.62, 2.69)
 0.18 (0.14, 0.22) 0.42 (0.34, 0.5) 0.49 (0.41, 0.59) 0.48 (0.37, 0.62) Osimertinib
OS
 Chemotherapy 0.97 (0.84, 1.12) 0.99 (0.83, 1.19) 1.11 (0.94, 1.31) 1.54 (1.19, 2.04)
 1.03 (0.89, 1.19) Gefitinib 1.02 (0.84, 1.24) 1.14 (0.96, 1.38) 1.59 (1.24, 2.07)
 1.01 (0.84, 1.21) 0.98 (0.80, 1.19) Erlotinib 1.11 (0.89, 1.41) 1.56 (1.22, 2.03)
 0.90 (0.76, 1.06) 0.88 (0.73, 1.05) 0.90 (0.7, 1.13) Afatinib 1.38 (1.04, 1.89)
 0.65 (0.49, 0.84) 0.63 (0.48, 0.81) 0.64 (0.49, 0.82) 0.72 (0.53, 0.96) Osimertinib
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the second-line osimertinib or pemetrexed-cisplatin, it was 
assumed that patients were treated with best supportive care 
(BSC) until death.
Utility weights
Health utility values reflecting the health-related quality of 
life in each health state were obtained from the literature 
[41]. The progression-free health state had the highest pos-
sible utility value while receiving TKI, with an estimated 
value of 0.71. This utility value was the same for all three 
TKI treatments. Progressive disease led to disutility for all 
TKIs. After progression on the first-line TKI treatment, the 
utility value was estimated at 0.67 (irrespective of post-
progression treatment with osimertinib or pemetrexed–cis-
platin) and after progression on the second-line treatment 
at 0.62 [41].
Disutility scores of severe adverse events (SAEs) with 
grades 3 or higher for the first-line gefitinib, erlotinib, 
afatinib, osimertinib, second-line osimertinib, and peme-
trexed-cisplatin were also included in the analyses. Occur-
rence of SAEs was extracted from the RCTs [11–19, 30–32] 
and were only included when at least 1.5% of the patients 
experienced a certain SAE. The disutility estimates were 
derived from the literature. The SAEs were assumed to all 
occur in the first simulation cycle of that specific treatment, 
since the adverse events commonly appear within the first 
weeks after starting these treatments [42, 43]. For the future 
effects, a discount rate of 1.5% was applied, according to 
the Dutch guidelines [28]. All utility values are presented 
in Table 2.
Costs
Following the Dutch guideline, a societal perspective was 
used for the model. Table 2 shows all unit costs of gefitinib, 
erlotinib, afatinib, and osimertinib treatment. Costs were 
based on the Dutch Costing manual, the Dutch Health Care 
Institute, Dutch Healthcare Authority, and the literature [27, 
44, 45]. All costs are in Euros, based on the average con-
sumer price index of 2018. Future costs were discounted by 
a rate of 4%, according to the Dutch guidelines [28]. More 
details on the costs can be found in Appendix II.
Sensitivity analyses
Since the cost-effectiveness model is based on a number 
of assumptions, several scenario analyses were performed 
to test the robustness of these assumptions. In the first sce-
nario tested, a log-logistic function instead of the Weibull 
function was used to estimate the survival probabilities in 
the model. Second, the chemotherapy patient group from 
another clinical trial (Lux-Lung 6) [17] was used to estimate 
the survival probabilities of gefitinib, erlotinib, afatinib, and 
osimertinib. Third, docetaxel instead of pemetrexed–cispl-
atin was included as the second-line treatment.
Deterministic (DSA) sensitivity analysis was performed 
to determine which input parameters of the model were most 
influential on the results of the model and to test the robust-
ness of the model. In this DSA, the impact of varying single 
input parameters on the cost-effectiveness ratio while hold-
ing the others constant was assessed. If available, the 95% 
confidence intervals (CI) of input estimates were used for the 
DSA. If not, parameters were varied with ± 20% of the mean. 
Probabilistic sensitivity analysis (PSA) was performed by 
simultaneously varying all the input parameters in a Monte 
Carlo simulation according to pre-specified distributions. 
Survival parameters lambda and gamma were assumed to be 
bivariate normal distributed, for utilities and probabilities, a 
beta distribution was applied and a gamma distribution was 
used for costs. Standard errors of utilities and probabilities 
were either obtained from the literature or calculated by 10% 
of the mean point estimate and 20% was used for the costs. 
In total, 1000 simulation samples were randomly drawn 
from the distributions of all inputs, and each time, the model 
results (incremental costs and incremental effects) were 
recalculated. We constructed a cost-effectiveness plane that 
shows the base-case ICER and the uncertainty surrounding 
the estimated costs and effects of the pairwise comparisons. 
Based on the cost-effectiveness plane, a cost-effectiveness 
acceptability curve was constructed, which shows the prob-
ability that a treatment is cost-effective compared to the 
alternative, given a range of threshold ICERs [46, 47].
Results
Base‑case results
Table 3 shows the incremental base-case results of the 
cost-effectiveness analyses. Gefitinib and erlotinib 
showed the lowest total discounted costs per patient and 
osimertinib had the highest estimated costs for patients 
with EGFR-mutated NSCLC. Osimertinib yielded the 
most effects, followed by afatinib, erlotinib, and gefi-
tinib. Compared to gefitinib, erlotinib resulted in a QALY 
gain of 0.03 (and 0.03 LYs) and cost savings of €1854 
per patient, indicating that erlotinib dominates gefitinib. 
Afatinib compared to erlotinib yielded 0.13 QALYs (and 
0.20 LYs) gained and a cost increase of €5383 per patient, 
which resulted in an ICER of €27,058/LY and €41,504/
QALY for afatinib versus erlotinib. Osimertinib yielded 
0.49 QALYs (and 0.68 LYs) and €62,579 more costs 
relative to afatinib. Thus, an additional €91,726 per LY 
and €128,343 per QALY gained is spent on osimertinib 
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Table 2  Input parameters for 
the model Base case Input DSA Distribution References
Costs
 Gefitinib per cycle €2526a Gamma [27]
 Erlotinib per cycle €2260a Gamma [27]
 Afatinib per cycle €2414a Gamma [27]
 Osimertinib per cycle €6106a Gamma [43]
 Pemetrexed/cisplatin per  cycleb €3029a Gamma [27]
 Best supportive care per cycle €1775 1377;  2065k Gamma [44]
 Mutation test €929 604;  906k Gamma [45]
 Tumour response  assessmentc €405 157;  236k Gamma [45]
 Outpatient visit €83 65;  97k Gamma [46]
 Laboratory  testsd €77 60;  89k Gamma [26]
 Drug administration €271 210;  315k Gamma [44]
 CNS progression osimertinib €535 428; 642 Gamma [47]
 CNS progression standard-TKI €1250 1000; 1500 Gamma [47]
 End-of-life €2196 1703;  2555k Gamma [48]
 Home care per hour €11 9;13 k Gamma [49]
 Indirect medical costs €10,602l 4578; 26,326 Gamma [50]
 Informal care per hour €14 11;  17k Gamma [49]
 Travelling €6e 5;  7k Gamma [46]
 Productivity loss €4068 3155;  4733k Gamma [51]
 ALT/AST increase €464 360;  540k Gamma [27]
 Anaemia €1953 1514;  2272k Gamma [49]
 Anorexia €797 618;  927k Gamma [52]
 Asthenia €813 631;  946f,k Gamma [49]
 Decreased appetite €826 640;  961k Gamma [49]
 Decreased white blood cells €1405 1089;  1634g,k Gamma [49]
 Diarrhoea €2359 1830;  2744k Gamma [49]
 Dyspnoea €467 362;  543k Gamma [27]
 Fatigue €813 631;  946k Gamma [49]
 Febrile neutropenia €3033 2353; 3,529k Gamma [49]
 Leukopenia €1942 1507;  2260k Gamma [49]
 Nausea €728 565;  847k Gamma [49]
 Neuropathy €795 616;  924k Gamma [49]
 Neutropenia €1405 1089;  1634k Gamma [49]
 Paronychia €2359j 1830;  2744k Gamma [49]
 Rash €2359 1830;  2744k Gamma [49]
 Stomatitis €4229 3280;  4920k Gamma [53]
 Vomiting €728i 565;  847k Gamma [49]
Utilities
 Progression-free 0.71 0.67; 0.80 Beta [40]
 After progression 0.67 0.59; 0.75 Beta [40]
 After progression on second line 0.62 0.49; 0.74 Beta [40]
Disutilities
 ALT/AST increase − 0 0;  0k Beta [54]
 Anaemia − 0.125 − 0.10; − 0.15k Beta [49]
 Anorexia − 0.142 − 0.114; − 0.170 Beta [55]
 Asthenia − 0.074f − 0.037; − 0.110 Beta [56]
 Decreased appetite − 0.048 − 0.016; − 0.080 Beta [49]
 Decreased white blood cells − 0.090g − 0.060; − 0.120 Beta [56]
 Diarrhoea − 0.047 − 0.016; − 0.078 Beta [56]
 Dyspnoea − 0.256 − 0.204; − 0.307k Beta [55]
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CNS central nervous system, DSA deterministic sensitivity analysis, OS overall survival, PFS progression-
free survival, ALT alanine aminotransferase; AST aspartate aminotransferase
a Costs comprised of acquisition costs and pharmaceutical delivery costs; no drug wastage assumed
b Volume pemetrexed/cisplatin based on a point estimate body surface of 1.70  m2. Administration of 
500 mg/m2 pemetrexed and 75 mg/m2 cisplatin each cycle
c Tumour response assessment comprised CT and MRI scans for tumour assessment
d Laboratory costs comprised haematology, sputum, and biochemistry test, excluding mutation test
e Based on 14 km (€0.19/km) plus parking costs (€3, –)
f Assumed to be the same as fatigue
g Assumed to be the same as neutropenia
h Assumed to be the same rash
i Assumed to be the same as nausea
j Assumed to be the same as rash
k Parameters were varied with ± 20% of the mean
l €10,602 are the average indirect medical costs over a lifetime horizon. Indirect medical costs ranged 
between €4578 and €26,326
Table 2  (continued) Base case Input DSA Distribution References
 Fatigue − 0.074 − 0.037; − 0.110 Beta [56]
 Febrile neutropenia − 0.090 − 0.058; − 0.122 Beta [49]
 Leukopenia − 0.090 − 0.059; − 0.120 Beta [49]
 Nausea − 0.048 − 0.016; − 0.080 Beta [56]
 Neuropathy − 0.048 − 0.016; − 0.080 Beta [49]
 Neutropenia − 0.090 − 0.060; − 0.120 Beta [56]
 Paronychia − 0.033j − 0.009; − 0.056 Beta [56]
 Rash − 0.033 − 0.009; − 0.056 Beta [56]
 Stomatitis − 0.151 − 0.121; − 0.181k Beta [57]
 Vomiting − 0.048 − 0.016; − 0.080 Beta [56]
 Body surface area 1.70 1.36; 2.04 Normal [49]
Parameters survival distribution
 Lambda OS chemotherapy 0.019 Normal
 Gamma OS chemotherapy 1.203 Normal
 Lambda OS gefitinib 0.020 Normal
 Gamma OS gefitinib 1.203 Normal
 Lambda OS erlotinib 0.019 Normal
 Gamma OS erlotinib 1.203 Normal
 Lambda OS afatinib 0.017 Normal
 Gamma OS afatinib 1.203 Normal
 Lambda OS osimertinib 0.012 Normal
 Gamma OS osimertinib 1.203 Normal
 Intercept OS second-line osimertinib 4.069 Normal
 Intercept OS second-line pemetrexed/cisplatin 2.861 Normal
 Lambda PFS chemotherapy 0.073 Normal
 Gamma PFS chemotherapy 1.478 Normal
 Lambda PFS gefitinib 0.031 Normal
 Gamma PFS gefitinib 1.478 Normal
 Lambda PFS erlotinib 0.026 Normal
 Gamma PFS erlotinib 1.478 Normal
 Lambda PFS afatinib 0.027 Normal
 Gamma PFS afatinib 1.478 Normal
 Lambda PFS osimertinib 0.013 Normal
 Gamma PFS osimertinib 1.478 Normal
 Intercept PFS second-line osimertinib 2.985 Normal
 Intercept PFS second-line pemetrexed/cisplatin 1.885 Normal
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compared to afatinib. The results of all other comparisons 
can be found in Appendix III.
Scenario analysis
Considering a Dutch threshold of €80,000/QALY, osimer-
tinib appears not to be cost-effective (ICER of osimerti-
nib vs. afatinib was €128,343/QALY). For osimertinib, 
a price reduction of 30% is required to be regarded as 
cost-effective (Appendix III).
Sensitivity analyses
Based on visual inspection, the Log-Logistic distribution 
for PFS can be regarded as a plausible alternative for the 
Weibull distribution. Since the Log-Logistic distribution 
also scored second for AIC and BIC (see Appendix II), 
we performed a scenario analysis using the Log-Logistic 
distribution to estimate the survival probabilities, which 
were then included into the model. This mainly resulted 
into lower incremental costs and a lower ICER for osimer-
tinib compared to afatinib. In another scenario, the chemo-
therapy patient group from the Lux-Lung 6 trial [17] was 
used instead of the EURTAC trial to estimate the survival 
probabilities of the TKIs. This scenario resulted in lower 
incremental costs and QALYs, especially for the comparison 
of osimertinib versus afatinib. Inclusion of another second-
line treatment than pemetrexed-cisplatin hardly affected the 
results (see Table C2 in Appendix III).
Since the comparison of osimertinib versus afatinib is 
most interesting (as gefitinib is dominated by erlotinib and 
afatinib is cost-effective compared to erlotinib), only the tor-
nado diagram of this comparison is presented here (Fig. 1). 
DSA showed that the utility value of the progression-free 
health state seemed to be the most influential drivers. The 
tornado diagrams of erlotinib versus gefitinib and of afatinib 
versus erlotinib can be found in Appendix III.
Figure 2 shows that almost 100% of the 1000 PSA itera-
tions were in the upper right quadrant, which means that 
more QALYs gained at additional costs for osimertinib 
compared to afatinib. For afatinib versus erlotinib, about 
Table 3  Base-case results of 
cost-effectiveness analyses
ICER incremental cost-effectiveness ratio, LYs life-years, QALYs quality-adjusted life-years, Δ difference in 
costs/effects
Comparison Costs (€) Costs 1st-line (€) LYs QALYs Δ Costs (€) Δ Effects ICER (€)
Gefitinib 65,889 39,467 2.01 1.36 – – –
Erlotinib 64,035 39,825 2.04 1.39 Dominates gefitinib
Afatinib 69,418 42,416 2.24 1.52 5383 0.13 41,504
Osimertinib 131,997 124,149 2.92 2.01 62,579 0.49 128,343
Fig. 1  Base-case Tornado diagram of the ICER of osimertinib vs. afatinib. ICER incremental cost-effectiveness ratio
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60% of the PSA iterations were in the upper right quad-
rant, 20% fell within the lower right quadrant, 10% in the 
upper left, and another 10% was in the lower left quad-
rant. For erlotinib compared to gefitinib, about 30% of the 
iterations fell within both the lower left and upper right 
quadrant, and about 20% fell within both the upper left and 
lower right quadrant. The cost-effectiveness acceptability 
curves (CEAC) of all TKIs are shown in Fig. 3. At a Dutch 
threshold of €80,000/QALY, afatinib had the highest prob-
ability of being cost-effective (43%). Gefitinib, erlotinib, 
and osimertinib had a probability of 13%, 19%, and 26%, 
respectively, of being cost-effective at the Dutch threshold. 
At a threshold of €200,000/QALY, the probability of being 
cost-effective was 75% for osimertinib.
Discussion
To the best of our knowledge, this was the first study in The 
Netherlands that compared the cost-effectiveness of first-line 
gefitinib, erlotinib, afatinib, and osimertinib for EGFR muta-
tion-positive (exon 19 deletion or exon 21 L858R mutation) 
Fig. 2  Cost-effectiveness plane of all comparisons. QALYs quality-adjusted life-years
Fig. 3  Cost-effectiveness 
acceptability curves. ICER 
incremental cost-effectiveness 
ratio
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NSCLC patients. Our study found that erlotinib dominated 
gefitinib. Afatinib resulted in a cost per QALY of €41,504 
compared to erlotinib. Compared to afatinib treatment, osi-
mertinib had an ICER of €128,343 per QALY gained. Thus, 
osimertinib was the most efficacious treatment option, fol-
lowed by afatinib, erlotinib, and gefitinib, but at a high cost.
Our results are similar to the results of Aguiar et al. with 
ICERs of $219,874/QALY of osimertinib vs. afatinib in the 
US and $175,432/QALY in Brazil [48]. In a report from the 
Dutch Health Care Institute (ZIN), osimertinib yielded an 
ICER of €324,006/QALY compared to gefitinib, erlotinib, 
and afatinib. An ICER range from €70,847 to €324,006 
was reported and the upper limit was used to calculate the 
required price reduction for osimerinib to be regarded as 
cost-effective (reduction of 55% at threshold of €80,000). 
The study submitted to ZIN used the effectiveness of only 
one trial (FLAURA trial), and thus, not all available evi-
dence was used to estimate the effectiveness of the drugs. 
Utility values for progression-free health state also differed: 
0.829 in the report versus 0.71 in this study [41, 49]. Since 
the utility values reported by the manufacturer were higher 
than previous reported utility values for this patient popula-
tion, these values were not used in this study. When we take 
these aspects into account, our results would be in the order 
of the findings of the ZIN report. In other cost-effectiveness 
studies, only two TKIs were compared [50–53]. Lee et al. 
[51] showed incremental costs per QALY gained by erlo-
tinib compared to gefitinib of $62,419 (incremental costs 
$14,061 and incremental QALY 0.23) and $41,494 per LY 
gained (incremental LY 0.34). These results are different 
from our study. This might be due to the fact that Lee et al. 
[51] simulated the survival probability for erlotinib based 
on the OS outcomes of the IPASS trial [18], because the OS 
results of erlotinib were still immature at that moment. In 
addition, more studies were included in our analyses. Ting 
et al. [50] analysed the cost-effectiveness of erlotinib versus 
afatinib and found a mean ICER of $61,809/QALY, with 
incremental costs $6417 and incremental QALY 0.17 [50]. 
These outcomes are the opposite of our results. A plausible 
reason might be that only the EURTAC and Lux-Lung 3 
trials were used for the data of erlotinib and afatinib, while 
we included various trials besides these two in our network 
[11–17, 19, 29–32]. Furthermore, Ting et al. [50] have cor-
rected the survival probabilities of erlotinib for patients with 
more severe disease. However, survival estimates were not 
corrected for other prognostic factors that were unequally 
distributed among the two treatments (e.g., EGFR mutation 
type). Correcting for only one prognostic factor could result 
into biased corrections. When uncorrected survival probabil-
ities were added in the study of Ting et al., erlotinib became 
less expensive and survival decreased. This yielded an ICER 
of $534,903 for afatinib versus erlotinib (incremental costs 
$7494 and incremental QALY 0.014) [50].
Our results were similar to the cost-effectiveness ratios 
reported by Chouaid et al. [53] and the National Institute 
of Health and care Excellence (NICE) [52]. Chouaid et al. 
[53] assessed the cost-effectiveness of afatinib compared 
to gefitinib by use of data from the Lux-Lung 7 trial, which 
resulted in incremental costs of €45,211 per QALY gained. 
The study by NICE yielded into a cost-effectiveness ratio 
of £10,076 per QALY gained of afatinib versus erlotinib 
[52].
However, our study had several limitations. The first 
limitation was the use of a model-based approach (based 
on published RCT data), due to a lack of real-world data. 
Consequently, the results and conclusions of our study are 
dependent on the validity of the assumptions made in our 
model. However, various alternative assumptions were 
assessed through sensitivity analyses, which showed the 
robustness of our results.
Second, the survival probabilities of gefitinib, erlotinib, 
afatinib, and osimertinib were estimated by use of the 
EURTAC trial, which was a trial with predominantly Cau-
casian population. However, we also included trials with 
predominantly Asian population in the model, since trials 
with non-Asian patients for all four TKIs were not available 
during study period. Although Asian ethnicity is one of the 
risk factors for EGFR mutations [8], two studies showed 
no significantly different risk of progression between Asian 
and non-Asian patients [15, 50]. Thus, use of studies with 
predominantly Asian population is not expected to bias the 
efficacy of TKIs. Therefore, to our opinion, the results of our 
study could be generalised to the Dutch population.
Due to a lack of relevant data on all TKIs, we were not 
able to perform subgroup analyses, e.g., patients with and 
without brain metastases. This could be regarded as a limi-
tation, as these analyses might give more insight into the 
cost-effectiveness of EGFR-TKIs in subgroups [54]. Since 
brain metastases occur less frequent in patients treated with 
osimertinib compared to patients treated with gefitinib or 
erlotinib, it is expected that the QALY gain for osimertinib 
will increase [19]. Thus, the ICER for this subgroup will be 
slightly lower compared to the outcomes for the total popu-
lation. As the occurrence of brain metastases might have a 
substantial impact on the outcomes, further research on these 
subgroups is needed.
Furthermore, at the time of our study, the OS results of the 
FLAURA trial were still immature. Therefore, interim analysis 
of OS was used in our model. However, the use of final OS 
results would be more desirable, because it reduces the uncer-
tainty of the model outcomes.
In addition, we assumed that patients treated with the 
first-line gefitinib, erlotinib, or afatinib all received the same 
second-line treatments with the same proportions, namely osi-
mertinib (50%) or pemetrexed–cisplatin (50%) and after pro-
gression on these second-line treatments, and patients were 
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treated with BSC. Though it may be reasonable that these 
proportions differ per TKI, we had no data to make such dis-
tinctions. Besides that, in reality, patients may also receive 
other second- or third-line treatments than those included in 
our model. In the ideal situation, we could fully account for 
the costs and effects of all second- and third-line treatments 
used in Dutch clinical practice. However, in the absence of any 
clear guidance on the second- and third-line treatment strate-
gies after TKI failure [55, 56], we considered our assumption 
a valid strategy. Scenario analysis also showed a marginal 
impact of different second-line treatments on the costs. In fur-
ther research, it is recommended to use real-world data of the 
first-line and second- and third-line treatment strategy, when 
it is available.
Furthermore, treatment costs could be overestimated 
somewhat as we did not adjust for dose reductions. However, 
adjustment for dose reductions is expected not to have a large 
impact on the cost-effectiveness results, since the costs related 
to osimertinib are high anyway. The assumption of no drug 
wastage is justified, because TKIs are pills and second-line 
pemetrexed–cisplatin was received by a relatively small pro-
portion of patients, which is expected to have a small amount 
of drug wastage. The effect on the incremental differences 
would be negligible. However, it might be more precise when 
drug wastage is taken into account where relevant.
The clinical effectiveness of osimertinib for patients with 
EGFR-mutated NSCLC is promising, as it could improve 
PFS and OS. Moreover, central nervous system (CNS) 
progression occurred less frequent in patients treated with 
osimertinib compared to standard-TKI [19]. Besides the 
substantial clinical relevance, the costs of treating CNS 
metastases will also be lower for osimertinib versus stand-
ard-TKI. Despite these benefits, our results showed that osi-
mertinib could not be regarded as cost-effective compared 
to all other TKIs. Therefore, it is of great importance to 
negotiate a lower price for osimertinib.
Conclusion
This study showed that the cost-effectiveness of afatinib 
compared to erlotinib is well below the Dutch threshold 
ratio of €80,000/QALY for treatments in this disease sever-
ity group. Osimertinib yielded a better effectiveness com-
pared to afatinib. However, the ICER of osimertinib versus 
afatinib (€128,343 per QALY gained) appears to be too high 
given the Dutch threshold. The price of osimertinib should 
be reduced by 30% to become cost-effective.
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